Search Results

• • 1,771 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Diabetes

  From:Formulary (Vol. 48, Issue 3) Peer-Reviewed

  Mar. 2013 Brief article, Table Diabetes New drugs Product type/ FDA status/notes proposed indication empagliflozin an oral, sodium/ phase 3 Boehringer glucose co/ Ingelheim/Eli Lilly transporter/2 (SGLT/ 2) inhibitor/for the reduction of blood...

• Brain insulin resistance in Alzheimer disease and its potential treatment with a Mediterranean diet and GLP-1 analogues

  Author:Konrad TalbotFrom:Psychiatric Times (Vol. 30, Issue 8) Peer-Reviewed

  Aug. 20134,051 words Article 1770LAlzheimer disease (AD) poses a public health risk of epidemic proportions worldwide. Until recently, it was defined as a type of dementia associated with abnormally high densities of amyloid-[beta] (A[beta]) plaques and...

• 4B Diabetes

  From:MPR Hematology and Oncology Edition (Vol. 6, Issue 3)

  Fall 20134,334 words Article 750LPRESCRIBING NOTES INSULIN is used in patients with type 1 diabetes (formerly known as insulin-dependent diabetes mellitus or IDDM). Insulin is also used in patients with type 2 diabetes (formerly known as non-insulin...

• Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide

  Authors:Maria Voukali, Irene Kastrinelli, Sapfo Stragalinou, Dimitra Tasiopoulou, Pinelopi Paraskevopoulou, Nicholas Katsilambros, et al.From:Journal of Diabetes Research (Vol. 2014) Peer-Reviewed

  Annual 20143,734 words Report 1430LTherapeutic approaches based on the actions of the incretin hormone GLP-1 have been widely established in the management of T2DM. Nevertheless, much less research has been aimed at elucidating the role of GLP-1 in lipid...

• Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment

  Authors:Jennie H. Best, Richard R. Rubin, Mark Peyrot, Yan Li, Ping Yan, Jaret Malloy, et al.From:Diabetes Care (Vol. 34, Issue 2) Peer-Reviewed

  Feb. 20114,846 words Clinical report 1530LOBJECTIVE--To assess change in patient-reported outcomes in subjects with type 2 diabetes treated with exenatide once weekly compared with those treated with sitagliptin or pioglitazone. RESEARCH DESIGN AND...

• Options for intensifying diabetes treatment

  Author:Timothy S. ReidFrom:Journal of Family Practice (Vol. 60, Issue 9) Peer-Reviewed

  Sept. 20112,447 words Article 1900LWhen the combination of intensive lifestyle modification and a maximally tolerated dose of metformin does not provide the glycemic control desired, there are several options for combination pharmacologic therapy....

• Antidiabetic activity of aqueous root extract of Ichnocarpus frutescens in streptozotocin-nicotinamide induced type-II diabetes in rats

  Authors:Rakesh Barik, Sanjay Jain, Deep Qwatra, Amit Joshi, Girraj Tripathi, and Ravi GoyalFrom:Indian Journal of Pharmacology (Vol. 40, Issue 1) Peer-Reviewed

  January-February 20082,017 words Clinical report 1560LByline: Rakesh. Barik, Sanjay. Jain, Deep. Qwatra, Amit. Joshi, Girraj. Tripathi, Ravi. Goyal Objective: To evaluate the antidiabetic activity of aqueous extract of roots of Ichnocarpus frutescens in...

• Diabetes: Glitazones may increase risk of oedema in heart failure

  Author:Matthew LockyerFrom:The PractitionerPeer-Reviewed

  June 29, 2007333 words Brief article, Clini... 1320LDr Matthew Lockyer GP, Suffolk and hospital practitioner in diabetic medicine A study published in the Journal of the American College of Cardiology has addressed the effect of rosiglitazone on left ventricular...

• Fournier Laboratories Ireland (Dublin, Ireland), a subsidiary of Solvay Pharmaceuticals (Brussels, Belgium), has withdrawn the European marketing authorization application it filed in July 2006 for Synordia, a type-2 diabetes treatment

  From:Applied Clinical Trials (Vol. 16, Issue 1) Peer-Reviewed

  Jan. 200754 words Brief article 1340LFournier Laboratories Ireland (Dublin, Ireland), a subsidiary of Solvay Pharmaceuticals (Brussels, Belgium), has withdrawn the European marketing authorization application it filed in July 2006 for Synordia, a type-2...

• Partial protective effect of rutin on multiple low dose streptozotocin-induced diabetes in mice

  Authors:K. Srinivasan, C. Kaul, and P. RamaraoFrom:Indian Journal of Pharmacology (Vol. 37, Issue 5) Peer-Reviewed

  September-October 20051,131 words Article Byline: K. Srinivasan, C. Kaul, P. Ramarao Type 1 diabetes or insulin-dependent diabetes mellitus (IDDM) is an autoimmune disorder affecting approximately 5.3 million people (mostly the children or young adults)...

• Thiazolidinediones for type 2 diabetes

  Authors:N Bradly Glazer, Wayman Wendell Cheatham, Alastair Benbow, Murray Stewart, and Guy YeomanFrom:British Medical Journal (Vol. 322, Issue 7280) Peer-Reviewed

  Jan. 27, 2001770 words Letter to the editor No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4 EDITOR--In their editorial on thiazolidinediones for type 2 diabetes Krentz et al incorrectly stated: "Pioglitazone induces...

• India bans diabetes drug

  From:British Medical Journal (Vol. 327, Issue 7423) Peer-Reviewed

  Nov. 8, 200341 words Brief article India bans diabetes drug: India's drugs controller general has finally banned the manufacture, sale, and distribution of the diabetes drug phenformin--citing potential risk to humans. It was withdrawn from the US market...

• NICE issues guidance on diabetes treatments

  Author:Andrew IlesFrom:British Medical Journal (Vol. 327, Issue 7414) Peer-Reviewed

  Sept. 6, 2003161 words Brief article 24 The use of thiazolidinediones (glitazones) for type 2 diabetes is to be restricted, after the release of new guidelines by the National Institute for Clinical Excellence (NICE). NICE recommends that the...

• Regimens using insulin analogs reduce low blood sugar episodes

  Author:Shauna S. RobertsFrom:Diabetes Forecast (Vol. 56, Issue 12)

  Dec. 2003630 words Article HAVE YOU tried various insulins, yet still can't get good control without low blood sugars (hypoglycemia)? If so, insulin analogs may help. Insulin analogs are lab-made human insulins that have been altered to change...

• Acute Effects of Pioglitazone on Glucose-Stimulated Insulin Release from [KKA.sup.y]-Mouse Islets

  Authors:JIAN-MAN LIN, GORAN SELEN, and PETER BERGSTENFrom:Diabetes (Vol. 49, Issue 5) Peer-Reviewed

  May 2000366 words Brief article Enhanced insulin action in target tissue after treatment with thiazolidinediones (TZDs) has focussed the interest of these substances as therapeutic agents for the treatment of type-2 diabetes. However, the compounds...

• Aminoguanidine-Pyridoxal Adduct Is Superior to Aminoguanidine in Preventing Experimental Diabetic Nephropathy

  Authors:HIDEAKI MIYOSHI, TADAO TAGUCHI, KATSUYUKI YANAGISAWA, KEN-ICHI TSUCHIDA, TAKAO KOIKE, ICHITOMO MIWA, et al.From:Diabetes (Vol. 49, Issue 5) Peer-Reviewed

  May 2000318 words Brief article Accumulation of AGE plays an important role in the complications of diabetes mellitus. Aminoguanidine is known to inhibit AGE formation and has been extensively examined in animals. However, aminoguanidine causes...

• Effects of metformin on glycemic control and cardiovascular risk factors

  Author:Matthew C. RiddleFrom:Clinical Diabetes (Vol. 13, Issue 1) Peer-Reviewed

  January-February 19951,029 words Article Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogin activator inhibitor in NIDDM subjects. Diabetes Care 16:621-629, 1993. SUMMARY Objective. To...

• New drug for type II: troglitazone increases insulin sensitivity

  Author:Marie McCarrenFrom:Diabetes Forecast (Vol. 50, Issue 5)

  May 19971,716 words Product/service eval... Troglitazone, a new drug to treat type II diabetes, was approved by the U.S. Food and Drug Administration (FDA) in January. It is now available, under the brand name Rezulin. Troglitazone works differently from the...

• Commentary on prevention a possible drug-drug interaction: Is concurrent administration of orlistat and pioglitazone increase the risk of durg-induced hepatotoxicity?

  Authors:Marjan Emzhik, Parvaneh Rahimi-Moghaddam, Soltan Ebrahimi, Fariborz Keyhanfar, and Ashraf MoazzamFrom:International Journal of Preventive Medicine (Vol. 6, Issue 1) Peer-Reviewed

  January-December 20151,616 words Article 1540LByline: Marjan. Emzhik, Parvaneh. Rahimi-Moghaddam, Soltan. Ebrahimi, Fariborz. Keyhanfar, Ashraf. Moazzam Background: Drug-drug interactions (DDIs) are an emerging threat to public health and are difficult to...

• Activation of AMPK by Bitter Melon Triterpenoids Involves CaMKK[beta]

  Authors:Tristan J. Iseli, Nigel Turner, Xiao-Yi Zeng, Gregory J. Cooney, Edward W. Kraegen, Sheng Yao, et al.From:PLoS ONE (Vol. 8, Issue 4) Peer-Reviewed

  Apr. 25, 20136,152 words Article 1480LAuthor(s): Tristan J. Iseli 1, Nigel Turner 1, Xiao-Yi Zeng 1,2, Gregory J. Cooney 1, Edward W. Kraegen 1, Sheng Yao 3, Yang Ye 3, David E. James 1, Ji-Ming Ye 1,2,3,* Introduction Type 2 diabetes (T2D) accounts...